UNITED STATES SECURITIES AND EXCHANGE COMMISSION August 28, 2008

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Hollis-Eden Pharmaceuticals, Inc.

File No. 0-24672 - CF# 22501

Hollis-Eden Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 16, 2006.

Based on representations by Hollis-Eden Pharmaceuticals, Inc., that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.52 through August 8, 2013

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Patti J. Dennis Chief, Office of Disclosure Support